{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:54:45Z","timestamp":1648986885302},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2007,7,15]],"date-time":"2007-07-15T00:00:00Z","timestamp":1184457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s00120-007-1519-y","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T00:29:33Z","timestamp":1184632173000},"page":"888-890","source":"Crossref","is-referenced-by-count":1,"title":["Pathophysiologie der Skelettmetastasierung urologischer Karzinome"],"prefix":"10.1007","volume":"46","author":[{"given":"G.","family":"Sauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.F.E.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,15]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0022-5347(05)65498-5","volume":"166","author":"Berruti","year":"2001","unstructured":"Berruti A, Dogliotti L, Tucci M et al. (2001) Metabolic bone disease induced by prostatic cancer: rationale for the use of bisphosphonates. J Urol 166: 2023\u20132031","journal-title":"J Urol"},{"key":"1519_CR2","doi-asserted-by":"crossref","first-page":"7178","DOI":"10.1158\/1078-0432.CCR-1004-0010","volume":"11","author":"Brouwers","year":"2005","unstructured":"Brouwers AH, Buijs WC, Mulders PF et al. (2005) Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res 11: 7178\u20137186","journal-title":"Clin Cancer Res"},{"key":"1519_CR3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-4598-6-18","volume":"6","author":"Desai","year":"2007","unstructured":"Desai B, Rogers M, Chellaiah MA (2007) Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 6: 18","journal-title":"Mol Cancer"},{"key":"1519_CR4","unstructured":"Dorfman HD, Czerniak B (1998) Metastatic Tumors in Bone. In: Dorfman HD, Czerniak B (eds) Bone Tumors. Mosby, St. Louis Baltimore Boston Carlsbad Chicago Minneapolis New York Philadelphia Portland London Milan Sydney Tokio Toronto, pp\u00a01009\u20131040"},{"key":"1519_CR5","first-page":"18","volume":"19","author":"Guise","year":"1998","unstructured":"Guise TA, Mundy GR (1998) Cancer and Bone. Endocr Rev 19: 18\u201354","journal-title":"Endocr Rev"},{"key":"1519_CR6","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1158\/1078-0432.CCR-05-1010","volume":"11","author":"Inoue","year":"2005","unstructured":"Inoue K, Karashima T, Fukata S et al. (2005) Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and Docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Cancer Res 11: 6669\u20136677","journal-title":"Clin Cancer Res"},{"key":"1519_CR7","unstructured":"Jundt G (2004) Skelettmetastasen. In: B\u00f6cker W, Denk H, Heitz PU (Hrsg) Pathologie 3. Aufl. Urban & Fischer, M\u00fcnchen Jena, S\u00a01057"},{"key":"1519_CR8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U","volume":"39","author":"Koeneman","year":"1999","unstructured":"Koeneman KS, Yeung F, Chung LW (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246\u2013261","journal-title":"Prostate"},{"key":"1519_CR9","first-page":"205","volume":"2","author":"Lipton","year":"2004","unstructured":"Lipton A (2004) Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J Support Oncol 2: 205\u2013220","journal-title":"J Support Oncol"},{"key":"1519_CR10","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1158\/1078-0432.CCR-040030","volume":"10","author":"Lipton","year":"2004","unstructured":"Lipton A, Colombo-Berra A, Bukowski RM et al. (2004) Skeletal complications in patients with bone metastasis from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10: 6397\u20136403","journal-title":"Clin Cancer Res"},{"key":"1519_CR11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","volume":"96","author":"Saad","year":"2005","unstructured":"Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96: 964\u2013969","journal-title":"BJU Int"},{"key":"1519_CR12","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1158\/1078-0432.CCR-06-0813","volume":"Res","author":"Vessella","year":"2006","unstructured":"Vessella C, Corey E (2006) Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res (Suppl 20) 12: 6285\u20136290","journal-title":"Clin Cancer"},{"key":"1519_CR13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000030361","volume":"62","author":"Wallmeroth","year":"1999","unstructured":"Wallmeroth A, Wagner U, Moch H et al. (1999) Patterns of metastasis in muscle-invasive bladder cancer. Urol Int 62:69\u201375","journal-title":"Urol Int"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-007-1519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-007-1519-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-007-1519-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:58:47Z","timestamp":1558609127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-007-1519-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s00120-007-1519-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}